389 related articles for article (PubMed ID: 25436731)
1. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
[TBL] [Abstract][Full Text] [Related]
2. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
3. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Walker BR
Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
[TBL] [Abstract][Full Text] [Related]
4. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
5. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
[TBL] [Abstract][Full Text] [Related]
6. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
9. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
10. Is there sufficient evidence to consider the use of 11β-hydroxysteroid dehydrogenase type 1 inhibition in children?
Fürst-Recktenwald S; Dörr HG; Quinkler M; Dötsch J; Stewart PM
Clin Endocrinol (Oxf); 2012 Aug; 77(2):159-68. PubMed ID: 22486586
[TBL] [Abstract][Full Text] [Related]
11. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus.
Hollis G; Huber R
Diabetes Obes Metab; 2011 Jan; 13(1):1-6. PubMed ID: 21114597
[TBL] [Abstract][Full Text] [Related]
12. Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.
Stimson RH; Andersson J; Andrew R; Redhead DN; Karpe F; Hayes PC; Olsson T; Walker BR
Diabetes; 2009 Jan; 58(1):46-53. PubMed ID: 18852329
[TBL] [Abstract][Full Text] [Related]
13. Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition.
Stimson RH; Andrew R; McAvoy NC; Tripathi D; Hayes PC; Walker BR
Diabetes; 2011 Mar; 60(3):720-5. PubMed ID: 21266326
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
Wamil M; Seckl JR
Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of adipose 11-beta-hydroxysteroid dehydrogenase type 1 expression in ovariectomized rats is due to obesity rather than lack of estrogen.
Paulsen SK; Nielsen MP; Richelsen B; Bruun JM; Flyvbjerg A; Pedersen SB
Obesity (Silver Spring); 2008 Apr; 16(4):731-5. PubMed ID: 18379559
[TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Paterson JM; Morton NM; Fievet C; Kenyon CJ; Holmes MC; Staels B; Seckl JR; Mullins JJ
Proc Natl Acad Sci U S A; 2004 May; 101(18):7088-93. PubMed ID: 15118095
[TBL] [Abstract][Full Text] [Related]
18. 11beta-Hydroxysteroid dehydrogenase Type 1: genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle.
Nair S; Lee YH; Lindsay RS; Walker BR; Tataranni PA; Bogardus C; Baier LJ; Permana PA
Diabetologia; 2004 Jun; 47(6):1088-95. PubMed ID: 15156315
[TBL] [Abstract][Full Text] [Related]
19. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
20. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Masuzaki H; Flier JS
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]